CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...
-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47 phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson’s Disease; expect to file IND and/or ...
Prime Medicine, Inc. CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one ...
A new village seal that pays homage to Skokie’s Indigenous peoples and the village’s history was approved by the Village Board on March 17. The new seal, with elements of a red flame, the Potawatomi ...
AMBOSS, the leading resource for medical education and clinical decision-making in Germany and the US, closes a €240M financing round with ...
(MENAFN- GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of ...
TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is pleased to announce that Miriam Martin, a long-standing member ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback